Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

ER+ breast cancers rely on oestrogen to grow and survive. Taking endocrine therapy with an aromatase inhibitor stops the body making oestrogen.

This starves the tumour of this hormone. This is why endocrine therapy with an aromatase inhibitor is very effective at both treating and preventing ER+ breast cancer.

It can also help ER+ breast cancers to shrink by stopping the ‘fuel’ that ER+ breast cancers use to grow. This is why we are using it in this study.